Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse: A Cautionary Tale

J Clin Psychiatry. 2024 Aug 26;85(3):24cr15378. doi: 10.4088/JCP.24cr15378.

Authors

Mark A Frye^{1

2}, Balwinder Singh¹, Scott A Breitinger¹, Tyler S Oesterle¹

Affiliations

¹ Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
² Corresponding Author: Mark A. Frye, MD, Department of Psychiatry and Psychology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 ([email protected]).

PMID: 39196888
DOI: 10.4088/JCP.24cr15378

No abstract available

MeSH terms

Adult
Alcoholism* / drug therapy
Hallucinogens / administration & dosage
Hallucinogens / adverse effects
Humans
Male
Psilocybin* / administration & dosage
Recurrence*
Selective Serotonin Reuptake Inhibitors* / administration & dosage
Selective Serotonin Reuptake Inhibitors* / adverse effects
Selective Serotonin Reuptake Inhibitors* / therapeutic use

Substances

Psilocybin
Selective Serotonin Reuptake Inhibitors
Hallucinogens